Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones - Collegium Pharmaceutical (NASDAQ:COLL)
Published on March 19, 2026.
The acquisition of the controversial pharmaceutical company, however, is not the first time it has occurred. The company is set to pay $650M in cash and potentially additional payments could exceed that amount depending on future milestones. The acquisition is part of a larger effort by the company to secure a contract with the manufacturer of pharmaceutical companies.
Related Articles
S&P 500 falls to a key technical spot. Traders watch whether it will hold
The S&P 500 faces a critical technical juncture, with the index falling below its 200-day mark amid rising inflation fears and Fed inaction.
Bitcoin falls below $70K as markets tumble after oil price spike
Markets and crypto markets are down as Bitcoin drops below $70,000 following a spike in oil prices and amid rising investor concerns about Iran's missile strikes.
Jabil Analysts Increase Their Forecasts After Better-Than-Expected Q2 Results - Jabil (NYSE:JBL)
Jabil's Q2 results surpassed analyst estimates, with increased full-year revenue and increased stock price targets.